Literature DB >> 1394063

The prognostic value of Ki-67 antigen in non-Hodgkin lymphoma of Waldeyer ring and the nasal cavity.

N Yamanaka1, Y Harabuchi, A Kataura.   

Abstract

BACKGROUND: A monoclonal antibody, Ki-67, recognizes an antigen expressed in all phases of the cell cycle, except G0, and can be used as a simple histologic marker of cell proliferation. To assess the prognostic value of the growth fraction in non-Hodgkin lymphoma of Waldeyer ring (W-NHL) and the nasal cavity (N-NHL), the authors applied Ki-67 immunostaining combined with image analysis on such lymphomas.
METHODS: The authors studied 29 patients (18 with W-NHL and 11 with N-NHL), applying Ki-67 to frozen sections. The number of Ki-67-positive cells in a unit area (0.044 mm2), as an indicator of proliferative activity, and the mean area per Ki-67-positive cell (microns2), as an indicator of DNA content, were measured by the image processing system.
RESULTS: High-grade lymphomas showed a significantly larger number of Ki-67-positive cells than intermediate-grade lymphomas (102.5 +/- 21.6 in high-grade and 46.8 +/- 8.92 in intermediate-grade lymphomas, P = 0.03), even when analyzed separately by immunophenotypes. A large mean area per Ki-67-positive cell was associated significantly with a T-cell phenotype (36.3 +/- 7.69 microns2 in T-cell lymphomas and 19.4 +/- 2.33 microns2 in B-cell lymphomas, P = 0.034) and an unfavorable clinical outcome. High proliferative activity, defined as nuclear Ki-67 expression in 2000 or more B-cell lymphoma cells and 1000 or more T-cell lymphoma cells in a 1-mm2 area, was found to be a strong predictor of poor survival among these patients (P = 0.048 and P = 0.009, respectively).
CONCLUSIONS: Ki-67 immunostaining, combined with image analysis, is a novel method for determining a tumor proliferative index that provides useful clinical data regarding head and neck lymphomas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394063     DOI: 10.1002/1097-0142(19921101)70:9<2342::aid-cncr2820700922>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  PCNA and Ki-67 in central nervous system tumors: correlation with the histological type and grade.

Authors:  Fazilet Kayaselçuk; Suzan Zorludemir; Derya Gümürdühü; Handan Zeren; Tahsin Erman
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

2.  Rhesus lymphocryptovirus type 1-associated B-cell nasal lymphoma in SIV-infected rhesus macaques.

Authors:  A K Marr-Belvin; A K Carville; M A Fahey; K Boisvert; S A Klumpp; M Ohashi; F Wang; S P O'Neil; S V Westmoreland
Journal:  Vet Pathol       Date:  2008-11       Impact factor: 2.221

3.  Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

Authors:  P Rudolph; T Lappe; C Schubert; D Schmidt; R M Parwaresch; E Christophers
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

4.  p27KIP1 is abnormally expressed in Diffuse Large B-cell Lymphomas and is associated with an adverse clinical outcome.

Authors:  A Sáez; E Sánchez; M Sánchez-Beato; M A Cruz; I Chacón; E Muñoz; F I Camacho; J C Martínez-Montero; M Mollejo; J F García; M A Piris
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

5.  Prognostic Significance of Bcl-2 and p53 Protein Expressions and Ki67 Proliferative Index in Diffuse Large B-cell Lymphoma.

Authors:  Betül Bolat Küçükzeybek; Sadi Bener; Aylin Orgen Çallı; Tuğba Doğruluk Paksoy; Bahriye Payzin
Journal:  Turk J Haematol       Date:  2013-09-05       Impact factor: 1.831

Review 6.  Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Toshiya Kamiyama; Tatsuhiko Kakisaka; Tatsuya Orimo; Kenji Wakayama
Journal:  World J Hepatol       Date:  2017-12-28

Review 7.  Paracrine control of tissue regeneration and cell proliferation by Caspase-3.

Authors:  K Boland; L Flanagan; J H M Prehn
Journal:  Cell Death Dis       Date:  2013-07-11       Impact factor: 8.469

8.  Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach.

Authors:  L Flanagan; M Meyer; J Fay; S Curry; O Bacon; H Duessmann; K John; K C Boland; D A McNamara; E W Kay; H Bantel; H Schulze-Bergkamen; J H M Prehn
Journal:  Cell Death Dis       Date:  2016-02-04       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.